SEARCH

SEARCH BY CITATION

References

  • 1
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 4947: 10418.
  • 2
    Travis SP. Review article: the management of mild to severe acute ulcerative colitis. Aliment Pharmacol Ther 2004; 20 (Suppl. 4): 8892.
  • 3
    Carbonnel F, Gargouri D, Lemann M, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000; 14: 2739.
  • 4
    Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 25560.
  • 5
    Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005; 1: CD004277.
  • 6
    Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther 2005; 22: 90716.
  • 7
    Garcia S, Gisbert JP, Gomollon F. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol 2005; 28: 60714.
  • 8
    Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593610.
  • 9
    Siddiqui MA, Scott LJ. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs 2005; 65: 2179208.
  • 10
    Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs 2005; 65: 225386.
  • 11
    Van Deventer SJ. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease – the mechanisms of action of infliximab. Aliment Pharmacol Ther 1999; 13 (Suppl. 4): 38; discussion 38.
  • 12
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398405.
  • 13
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 15419.
  • 14
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 87685.
  • 15
    Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease - seven years on. Aliment Pharmacol Ther 2006; 23: 45163.
  • 16
    D'Haens G. Infliximab for ulcerative colitis: finally some answers. Gastroenterology 2005; 128: 21614.
  • 17
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 112.
  • 18
    Seiderer J, Goke B, Ochsenkuhn T. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital. Digestion 2004; 70: 39.
  • 19
    Actis GC, Bruno M, Pinna-Pintor M, Rossini FP, Rizzetto M. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis 2002; 34: 6314.
  • 20
    Armuzzi A, De Pascalis B, Lupascu A, et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 2004; 8: 2313.
  • 21
    Armuzzi A, Lupascu A, De Pascalis B, et al. Infliximab in the treatment of glucocorticoid-dependent ulcerative colitis: a 54-week randomized methylprednisolone-controlled trial. Gastroenterology 2005; 128 (Suppl. 2): W1008.
  • 22
    Bermejo F, Lopez-Sanroman A, Hinojosa J, Castro L, Jurado C, Gomez-Beldal AB. Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis. Rev Esp Enferm Dig 2004; 96: 94101.
  • 23
    Branciforte G, Terminella C, Bentivegna C, Scalia A, Catalano F. Is infliximab an useful therapeutic agent for ulcerative colitis? Gut 2002; 51 (Suppl. III): A217.
  • 24
    Castro Fernandez M, Garcia Diaz E, Romero M, Galan Jurado V, Rodriguez Alonso C. Treatment of steroid-refractory ulcerative colitis with infliximab. Gastroenterol Hepatol 2003; 26: 545.
  • 25
    Chey WY, Hussain A, Ryan C, Potter GD, Shah A. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001; 96: 237381.
    Direct Link:
  • 26
    Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001; 7 (Suppl. 1): S303.
  • 27
    Cooper JM, Patterson D, Thirlby RC. Infliximab for ulcerative colitis: not a cure for severe disease. Gastroenterology 2003; 124 (Suppl.1): 0A818.
  • 28
    De Falco R, Cirillo M, Gennarelli N, et al. Infliximab for the treatment of ulcerative recto-colitis unresponsive to conventional corticosteroid therapy. Endoscopic evaluation. Gut 2005; 54 (Suppl. VII): A155.
  • 29
    Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 2005; 11: 2138.
  • 30
    Fleisher MR, Rubin SD, Levine AE, et al. Infliximab in the treatment of steroid-naïve ulcerative colitis. Am J Gastroenterol 2001; 96 (Suppl.): S2912.
  • 31
    Frenz M, Simmons J, Travis S, Jewell D. Treatment and re-treatment of severe ulcerative colitis with infliximab: a case study. Inflamm Bowel Dis Monitor 2002; 3: 11920.
  • 32
    Gornet JM, Couve S, Hassani Z, et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther 2003; 18: 17581.
  • 33
    Jarnerot G, Blombert B, Bohr J, Curman B, Sandberg-Gertzén H. Infliximab (Remicade) as rescue therapy in acute corticosteroid-resistant ulcerative colitis (UC). Scand J Gastroenterol 2001; 36 (Suppl. 233): 08.
  • 34
    Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 180511.
  • 35
    Jølle T, Guanglin C, Goll R, et al. Anti-TNF-alpha (infliximab) treatment suppresses tissue TNF-alpha mRNA expression and induces clinical remission in ulcerative colitis. Gut 2004; 53 (Suppl. VI): A310.
  • 36
    Kaser A, Mairinger T, Vogel W, Tilg H. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr 2001; 113: 9303.
  • 37
    Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis 2002; 34: 62630.
  • 38
    Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M. Infliximab in the treatment of severe ulcerative colitis: a follow-up study. Eur Rev Med Pharmacol Sci 2004; 8: 2357.
  • 39
    Kountouras J, Zavos C, Chatzopoulos D. Anti-tumor necrosis factor therapy for ulcerative colitis. Gastroenterology 2005; 129: 11389.
  • 40
    Sapakos I, Gavalas E, Zavos C, et al. Infliximab administration in patients with ulcerative colitis. In: Proceedings of the Fourth Panhellenic Congress of Inflammatory Bowel Diseases. Thessaloniki, Greece, 2005: 234.
  • 41
    Kugathasan S, Prajapati D, Kim CP, et al. Infliximab outcome in children and adults with ulcerative colitis. Gastroenterology 2002; 120: A615.
  • 42
    Lim W, Sparrow MP, Hanauer S. The efficcacy of infliximab (INF) in ulcerative colitis (UC) – the University of Chicago's experience. Gastroenterology 2005; 128 (Suppl. 2): W1035.
  • 43
    Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53: 84953.
  • 44
    Mamula P, Markowitz JE, Brown KA, Hurd LB, Piccoli DA, Baldassano RN. Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2002; 34: 30711.
  • 45
    Mamula P, Markowitz JE, Cohen LJ, Von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr 2004; 38: 298301.
  • 46
    McGinnis JK, Murray KF. Infliximab for ulcerative colitis in children. J Pediatr Gastroenterol Nutr 2004; 39 (Suppl. 1): S282.
  • 47
    Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004; 16: 116771.
  • 48
    Oliva-Hemker M, Roper S, Cuffari C, Leibowitz I. Infliximab therapy for pediatric ulcerative colitis. Gastroenterology 2002; 122: A616.
  • 49
    Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 52: 9981002.
  • 50
    Ruiz P, San Salvador P, Ortiz de Zarate J, et al. Infliximab as treatment for a severe outbreak of ulcerative colitis. Gastroenterol Hepatol 2004; 27: 4301.
  • 51
    Russell GH, Katz AJ. Infliximab is effective in acute but not chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr 2004; 39: 16670.
  • 52
    Rutgeerts P, Feagan B, Olson A, et al. A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: Act I trial. Gastroenterology 2005; 128 (Suppl. 2): 689.
  • 53
    Sandborn WJ, Feagan B, Olson A, et al. A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: Act I trial results through week 54. Am J Gastroenterol 2005; 100 (Suppl): S313.
  • 54
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 246276.
  • 55
    Sandborn WJ, Rachmilewitz D, Hanauer S, et al. Infliximab induction and maintenance therpay for ulcerative colitis: the Act 2 trial. Gastroenterology 2005; 128 (Suppl.2): 688.
  • 56
    Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 7: 838.
  • 57
    Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, Brown RF, Udall JN Jr, Mannick EE. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001; 35: 8238.
  • 58
    Sriram PV, Reddy KS, Rao GV, Santosh D, Reddy DN. Infliximab in the treatment of ulcerative colitis with toxic megacolon. Indian J Gastroenterol 2004; 23: 223.
  • 59
    Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002; 97: 257784.
    Direct Link:
  • 60
    Shen EH, Das KM. Current therapeutic recommendations: infliximab for ulcerative colitis. J Clin Gastroenterol 2004; 38: 7415.
  • 61
    Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 41729.
  • 62
    Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32: 9137.
  • 63
    Lichtenstein GR. Is infliximab effective for induction of remission in patients with ulcerative colitis? Inflamm Bowel Dis 2001; 7: 8993.
  • 64
    Nielsen OH, Gionchetti P, Ainsworth M, et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 1999; 94: 29238.
  • 65
    Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol 1999; 34: 6674.
  • 66
    Guimbaud R, Bertrand V, Chauvelot-Moachon L, et al. Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis. Am J Gastroenterol 1998; 93: 2397404.
    Direct Link:
  • 67
    Saiki T, Mitsuyama K, Toyonaga A, Ishida H, Tanikawa K. Detection of pro- and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease. Scand J Gastroenterol 1998; 33: 61622.
  • 68
    Reimund JM, Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996; 16: 14450.
  • 69
    Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 17481.
  • 70
    Tsukada Y, Nakamura T, Iimura M, Iizuka BE, Hayashi N. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol 2002; 97: 28208.
    Direct Link:
  • 71
    Watkins PE, Warren BF, Stephens S, Ward P, Foulkes R. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Gut 1997; 40: 62833.
  • 72
    Evans RC, Clarke L, Heath P, Stephens S, Morris AI, Rhodes JM. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther 1997; 11: 10315.
  • 73
    A-Rahim YI, Farrell RJ. Anti-tumor necrosis factor therapy in ulcerative colitis. UpToDate 2005; 13: 16.
  • 74
    Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89: 100513.
  • 75
    Rossetti S, Actis GC, Fadda M, Rizzetto M, Palmo A. The use of the anti-tumour necrosis factor monoclonal antibody – infliximab – to treat ulcerative colitis: implications and trends beyond the available data. Dig Liver Dis 2004; 36: 42631.
  • 76
    Fuss IJ. Treatment of ulcerative colitis with infliximab: are we there yet? J Pediatr Gastroenterol Nutr 2004; 38: 2479.
  • 77
    MacDermott RP, Lichtenstein GR. Infliximab (Remicade) in Crohn's disease. UpToDate 2005; 13: 111.
  • 78
    Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002; 123: 70713.
  • 79
    Blomberg B, Jarnerot G. Clinical evaluation and management of acute severe colitis. Inflamm Bowel Dis 2000; 6: 21427.
  • 80
    Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004; 10: 738.
  • 81
    Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 94087.
  • 82
    Su C. Outcomes of placebo therapy in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 32833.
  • 83
    Jarnerot G. Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology 2006; 130: 286, author reply 287.